Biography
Selected Publications
Contact Information

Biography

Emanuel N. Vergis, M.D., M.P.H. is an Assistant Professor of Medicine and a member of its HIV-AIDS Unit. He is also the Program Director for the Infectious Diseases fellowship training program, and is responsible for the teaching and educational efforts of the Division as they relate primarily to the School of Medicine, as well as to house staff and fellows. His research has focused on community-acquired pneumonia, nosocomial pneumonia in long-term care patients, resistant enterococcal infections, and salvage therapy for chronically HIV-infected individuals. He is a co-investigator on the Adult AIDS Clinical Trials Group (AACTG) protocol A5086 which will study structured treatment interruptions in HIV-infected individuals having limited drug salvage therapeutic options. He is also co-chairperson on AACTG protocol A5143 which will study the efficacy of triple protease inhibitor treatment in HIV-infected individuals having prior extensive antiretroviral treatment experience resulting in limited therapeutic options.

Selected Publications

1. Vergis EN, Brenner C, Wagener MM, Muder RR. Pneumonia in long-term care: A prospective case-control study of risk factors and impact on survival Arch Intern Med 2001; 161:2378-2381.
   
   
2. Vergis EN, Paterson DL, Wagener MM, Swindells S, Singh N. Dyslipidaemia in HIV-infected patients: Association with adherence to potent antiretroviral therapy. International J STD AIDS 2001; 12:463-8.
   
   
3. Vergis EN, Hayden MK, Chow JW, Snydman DR, Zervos MJ, Linden PK, Wagener MM, Schmitt B, Muder RR. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia: a prospective multicenter study. Ann Intern Med 2001:135:484-492.
   
   
4. Vergis EN, Demas PN, Vaccarello SJ, Yu VL. Topical antibiotic prophylaxis for bacteremia after dental extractions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 91:162-5.
   
   
5. Vergis EN, Indorf A, File TM, Phillips J, Bates J, Tan J, Indorff A, Sarosi GA, Grayston JT, Summersgill J, Yu VL. Azithromycin versus cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospital patients: A prospective, randomized, multicenter trial. Arch Intern Med 2000; 160:1294-1300.
   
   
6. Dorman JS, Bunker CH, Brach JS, Ezzedine RZ, Forlenza MJ, Gathuru IM, Gibbon JL, Hagan MA, Lee LL, Loucks TL, Luedecking EK, McFarland CE, Pollice C, Rager JR, Riddler SA, Riechman SE, Schmidt NJ, Stricklin DL, Truitt TM, Vergis EN, Wildman RP, Willenkin RG, Winters CS. HLA-DQ and type 1 diabetes. HuGE Review. 2000.
   
   
7. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Aquier C, Wagener MM, Singh N. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30.
   
   
8. Vergis EN, Akbas E, Yu VL. Legionella as a cause of severe pneumonia. Sem Respir Crit Care Med 2000; 21:295-304.
   
   
9. Vergis EN, Mellors JW. Natural history of HIV-1 infection. Infect Dis Clinics of NA 2000; 14:809-825.
   
   
10. Vergis EN, Yu VL. New directions for future studies of community-acquired pneumonia: Optimizing impact on patient care. Eur J Clin Microbiol Infect Dis 1999; 18:847-51.
    
    
11. Yu VL, Vergis EN. New macrolides or new quinolones as monotherapy for patient with community-acquired pneumonia: Our cup runneth over? Chest 1998; 113:1158-1159.
    
    
12. Vergis EN, Paterson DL, Singh N. Indinavir-associated hepatitis in patients with advanced HIV infection. International J STD/AIDS 1998; 9:53.
    
    
13. Vergis EN, Montessori V, Montaner, J, Mellors JW. Proceedings from the International Workshop on Salvage Therapy for HIV Infection, New Orleans, LA, 1998. Antiviral Therapy 1998; 3:1-22.
    
    
14. Vergis EN, Yu VL. Macrolides are ideal for empiric therapy of community-acquired pneumonia in the immunocompetent host. Sem Resp Infect 1997; 12:322-328.